STRATEC SE

M&A Activity • Sep 30, 2004

News Details

Corporate | 30 September 2004 10:00

STRATEC and BIOTEST conclude agreement on further development of TANGO

Corporate-news announcement sent by DGAP. The sender is solely responsible for the contents of this announcement. ——————————————————————————– STRATEC and BIOTEST renew cooperation STRATEC Biomedical Systems AG and Biotest AG conclude agreement on further development and supply of TANGO, the fully automated blood grouping analyzer Birkenfeld/Dreieich, September 30, 2004 STRATEC Biomedical Systems AG, Birkenfeld, and Biotest AG, Dreieich, concluded an agreement in September 2004 for the further development and supply of TANGO, the fully automated blood grouping analyzer. In view of the FDA approval expected for the start of 2005, TANGO, which Biotest already sells on the European market, will be modified for the requirements of the US diagnostics market and equipped with additional functions and further-developed technologies. Filing for TANGO’s and the associated reagents’ FDA (Food and Drug Administration) approval is a key milestone for Biotest in further marketing this blood grouping device. In order to penetrate the US market, Biotest has entered into a strategic sales alliance with Olympus America Inc., one of the market leaders for fully automated blood grouping serology in North America. This distribution agreement is also valid for the Canadian market, where the approval was already achieved by Olympus. The TANGO analyzer automates the complete blood group typing and antibody screening, and its standardized method guarantees a high degree of security when conducting blood-group serum tests. It replaces lengthy manual processing stages and hand-written documentation, and thus allows scarce resources to be used more economically. About Biotest AG Biotest AG’s activities focus on its two divisions of Diagnostics and Pharmaceuticals in the fields of medical transfusions and transplantations, autoimmune diseases, infections and hygiene control. Biotest AG’s shares are admitted to Prime Standard trading. About STRATEC Biomedical Systems AG STRATEC AG (http://www.stratec-biomedical.de) designs and manufactures fully automated systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems together with their own reagents to laboratories and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (WKN: 728900 / ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange, in the trading segment Gate-M of the Stuttgart Stock Exchange and on other exchanges. For further information please contact: STRATEC Biomedical Systems AG Investor Relations André Loy Gewerbestrasse 37 75217 Birkenfeld, Germany Telephone: +49 (0)7082 7916-190 Telefax: +49 (0)7082 7916-999 E-mail: ir@stratec-biomedical.de Biotest AG Head of PR/IR Hubert Bötsch Landsteinerstrasse 5 63303 Dreieich, Germany Telephone: +49 (0)6103 801-444 Telefax: +49 (0)6103 801-880 E-mail: hubert_boetsch@biotest.de end of message, (c)DGAP 30.09.2004 ——————————————————————————– WKN: 728900; ISIN: DE0007289001; Index: Listed: Geregelter Markt in Frankfurt (Prime Standard) und Stuttgart; Freiverkehr in Berlin-Bremen, Düsseldorf und München 301000 Sep 04